CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice
Paula Kolar
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Search for more papers by this authorJ. Kolja E. Hegel
University Hospital Magdeburg, Magdeburg, Germany
Search for more papers by this authorDagmar Quandt
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Search for more papers by this authorGerd-R. Burmester
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Dr. Burmester has received consulting fees, speaking fees, and/or honoraria (less than $10,000) as well as (together with Dr. Brunner-Weinzierl) an unrestricted research grant from Bristol-Myers Squibb.
Search for more papers by this authorHolger Hoff
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Search for more papers by this authorCorresponding Author
Monika C. Brunner-Weinzierl
Deutsches Rheuma-Forschungszentrum, Berlin, Charité–University Hospital, Berlin, and University Hospital Magdeburg, Magdeburg, Germany
Department of Paediatrics, University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, GermanySearch for more papers by this authorPaula Kolar
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Search for more papers by this authorJ. Kolja E. Hegel
University Hospital Magdeburg, Magdeburg, Germany
Search for more papers by this authorDagmar Quandt
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Search for more papers by this authorGerd-R. Burmester
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Dr. Burmester has received consulting fees, speaking fees, and/or honoraria (less than $10,000) as well as (together with Dr. Brunner-Weinzierl) an unrestricted research grant from Bristol-Myers Squibb.
Search for more papers by this authorHolger Hoff
Deutsches Rheuma-Forschungszentrum Berlin, and Charité–University Hospital, Berlin, Germany
Search for more papers by this authorCorresponding Author
Monika C. Brunner-Weinzierl
Deutsches Rheuma-Forschungszentrum, Berlin, Charité–University Hospital, Berlin, and University Hospital Magdeburg, Magdeburg, Germany
Department of Paediatrics, University Hospital Magdeburg, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, GermanySearch for more papers by this authorAbstract
Objective
CD4+CD25+ regulatory T cells (known as Treg cells) suppress unwanted and autoreactive T cell responses. Treg cells express the costimulatory molecule CTLA-4 intracellularly, but the mechanisms by which Treg cells exploit CTLA-4 signaling remain unclear. The present study was undertaken to investigate the role of CTLA-4 in controlling the homeostasis and suppressive function of Treg cells.
Methods
Murine Treg cells were analyzed by flow cytometry for coexpression of CTLA-4 and typical Treg cell–expressed molecules, and the influence of CTLA-4 on T cell proliferation, suppression, and apoptosis was investigated by in vitro assays. To analyze the importance of CTLA-4 in Treg cell–mediated suppression in vivo, wild-type Treg cells were transferred into CTLA-4–deficient mice displaying lymphoproliferation, and survival was monitored over time.
Results
A strong correlation between expression of forkhead box P3 and ex vivo expression of CTLA-4 in Treg cells was observed. Inhibition of CTLA-4 signaling in Treg cells during in vitro stimulation increased cell cycling and led to enhanced activation-induced cell death (AICD), which was mediated by CD95/CD95 ligand–induced activation of caspases. Blockade of CTLA-4 signaling resulted in impairment of the suppressive capacity of Treg cells. Despite these effects, high amounts of Treg cells persisted in CTLA-4–deficient mice. Results of transfer experiments in CTLA-4–deficient mice showed that the mice had a significantly prolonged lifespan when CTLA-4–competent Treg cells were injected.
Conclusion
Expression of CTLA-4 on Treg cells serves to control T cell proliferation, to confer resistance against AICD, and to maintain the suppressive function of Treg cells.
REFERENCES
- 1 Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–86.
- 2 Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-β requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 2006; 176: 3321–9.
- 3 Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151–64.
- 4 Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, et al. Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303–10.
- 5 Von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol 2005; 6: 338–44.
- 6 Huehn J, Siegmund K, Lehmann JC, Siewert C, Haubold U, Feuerer M, et al. Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004; 199: 303–13.
- 7 Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005; 6: 331–7.
- 8 Chai JG, Xue SA, Coe D, Addey C, Bartok I, Scott D, et al. Regulatory T cells, derived from naive CD4+CD25− T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. Transplantation 2005; 79: 1310–6.
- 9 Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005; 22: 329–41.
- 10 Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6: 745–51.
- 11 Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816–22.
- 12 Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6: 345–52.
- 13 Kelchtermans H, De Klerck B, Mitera T, Van Balen M, Bullens D, Billiau A, et al. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-γ. Arthritis Res Ther 2005; 7: R402–15.
- 14 Morgan ME, Witteveen HJ, Sutmuller RP, de Vries RR, Toes RE. CD25+ regulatory cells from HLA-DQ8 transgenic mice are capable of modulating collagen-induced arthritis. Hum Immunol 2004; 65: 1319–27.
- 15 Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 2003; 48: 1452–60.
- 16 Frey O, Petrow PK, Gajda M, Siegmund K, Huehn J, Scheffold A, et al. The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells. Arthritis Res Ther 2005; 7: R291–301.
- 17 Loughry A, Fairchild S, Athanasou N, Edwards J, Hall FC. Inflammatory arthritis and dermatitis in thymectomized, CD25+ cell-depleted adult mice [published erratum appears in Rheumatology (Oxford) 2005;44:569]. Rheumatology (Oxford) 2005; 44: 299–308.
- 18 Nguyen LT, Jacobs J, Mathis D, Benoist C. Where FoxP3-dependent regulatory T cells impinge on the development of inflammatory arthritis. Arthritis Rheum 2007; 56: 509–20.
- 19 Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases: a general susceptibility gene to autoimmunity? Genes Immun 2000; 1: 170–84.
- 20 Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506–11.
- 21 Van der Auwera BJ, Vandewalle CL, Schuit FC, Winnock F, De Leeuw IH, Van Imschoot S, et al, the Belgian Diabetes Registry. CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers. Clin Exp Immunol 1997; 110: 98–103.
- 22 Barreto M, Santos E, Ferreira R, Fesel C, Fontes MF, Pereira C, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 2004; 12: 620–6.
- 23 Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000; 31: 49–53.
- 24 Waterhouse P, Bachmann MF, Penninger JM, Ohashi PS, Mak TW. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. Eur J Immunol 1997; 27: 1887–92.
- 25 Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541–7.
- 26 Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 985–8.
- 27 Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813–20.
- 28 Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, et al. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 1996; 153: 27–46.
- 29 Pandiyan P, Gartner D, Soezeri O, Radbruch A, Schulze-Osthoff K, Brunner-Weinzierl MC. CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J Exp Med 2004; 199: 831–42.
- 30 Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295–302.
- 31 Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168: 1080–6.
- 32 Scheffold A, Assenmacher M, Reiners-Schramm L, Lauster R, Radbruch A. High-sensitivity immunofluorescence for detection of the pro- and anti-inflammatory cytokines gamma interferon and interleukin-10 on the surface of cytokine-secreting cells. Nat Med 2000; 6: 107–10.
- 33 Lehmann J, Huehn J, de la Rosa M, Maszyna F, Kretschmer U, Krenn V, et al. Expression of the integrin αEβ7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells. Proc Natl Acad Sci U S A 2002; 99: 13031–6.
- 34 Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389–400.
- 35 Powrie F, Maloy KJ. Immunology: regulating the regulators. Science 2003; 299: 1030–1.
- 36 Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, et al. CD4+CD25+ regulatory T cells can mediate suppressor function in the absence of transforming growth factor β1 production and responsiveness. J Exp Med 2002; 196: 237–46.
- 37 Maszyna F, Hoff H, Kunkel D, Radbruch A, Brunner-Weinzierl MC. Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J Immunol 2003; 171: 3459–66.
- 38 Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp 2003; 252: 55–63.
- 39 Hoff H, Burmester GR, Brunner-Weinzierl MC. Competition and cooperation: signal transduction by CD28 and CTLA-4. Signal Transduct 2006; 6: 260–7.
- 40 Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172: 4100–10.
- 41 Piconi S, Trabattoni D, Iemoli E, Fusi ML, Villa ML, Milazzo F, et al. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2002; 128: 59–66.
- 42 Konttinen YT, Salo T, Hanemaaijer R, Valleala H, Sorsa T, Sutinen M, et al. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999; 18: 401–12.
- 43 Fritzsching B, Oberle N, Eberhardt N, Quick S, Haas J, Wildemann B, et al. In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 2005; 175: 32–6.
- 44 Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003; 198: 249–58.
- 45 Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. Nat Immunol 2002; 3: 33–41.
- 46 Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Blue-stone JA. Distinct roles of CTLA-4 and TGF-β in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34: 2996–3005.
- 47 Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58: 953–63.
- 48 Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 2007; 3: 619–26.
- 49 Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330–6.
- 50 Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337–42.
